Trial Profile
Phase II Single Arm Study to Assess Dinutuximab (Ch 14.18) Combined With the Cytokines Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) and IL-2 in Patients With High-risk Neuroblastoma Not Eligible to Other Immunotherapy Trials
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dinutuximab (Primary) ; Granulocyte macrophage colony stimulating factor; Interleukin-2; Isotretinoin; Sargramostim
- Indications Neuroblastoma
- Focus Adverse reactions
- 31 May 2020 Results (from EudraCT 2013-004864-69 and EudraCT 017-001829-40) performing retrospective analysis of event-free survival and overall survival in high-risk neuroblastoma patients, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 08 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Oct 2016 Planned number of patients changed from 10 to 25.